61 filings
8-K
SABS
SAB Biotherapeutics Inc
21 May 24
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US
7:30am
8-K
SABS
SAB Biotherapeutics Inc
15 Apr 24
Regulation FD Disclosure
5:15pm
8-K
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
8-K
SABS
SAB Biotherapeutics Inc
8 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
SABS
SAB Biotherapeutics Inc
2 Feb 24
SAB Biotherapeutics Announces Executive Leadership Change
7:53am
8-K
46uar2xjbpc
26 Jan 24
Entry into a Material Definitive Agreement
4:15pm
8-K
5pw1c4
25 Jan 24
Other Events
5:00pm
8-K
jagsm ujg
19 Jan 24
Regulation FD Disclosure
4:21pm
8-K
tx2bi72dg2k51bm
3 Jan 24
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
9:00am
8-K
lhmdp57
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
8-K
nh06iziv1yt1swk09
22 Nov 23
Amendments to Articles of Incorporation or Bylaws
4:45pm
8-K
fui5ud3g1d8b0152mlw6
20 Nov 23
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
5:00pm
8-K/A
4s8t na6l7zumf
14 Nov 23
Unregistered Sales of Equity Securities
4:31pm
8-K
0sfw27tuju
27 Oct 23
Entry into a Material Definitive Agreement
5:00pm
8-K
1v1dnhknq nqzb
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
8-K
oegpbu8cdswho1 rf
21 Aug 23
Changes in Registrant's Certifying Accountant
8:25am
8-K
nqrr8hsq
31 Jul 23
Changes in Registrant's Certifying Accountant
4:43pm
8-K
0h0vndtm9 2qf4
3 Jul 23
Submission of Matters to a Vote of Security Holders
1:20pm
8-K
gmlncb0tcejfcpz8w
21 Jun 23
Regulation FD Disclosure
8:50am
8-K
dre3wo
14 Jun 23
Regulation FD Disclosure
8:53am